COLUMBIA, Md.--(BUSINESS WIRE)--Heartscape Technologies, Inc. has announced enrollment today of the first patient in the OCCULT-MI trial. The Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT-MI) trial will measure the impact of a more complete view of the electrical signals of the heart with the PRIME ECG® System (“PRIME”), compared with the standard ECG, including time to treatment (cardiac catheterization sheath placement) for patients diagnosed using PRIME versus the time to treatment using the standard 12-lead electrocardiogram.
